A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I, nonrandomized, open-label multiple-dose study evaluated pexidartinib safety and efficacy in Asian patients with symptomat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jih-Hsiang, Chen, Tom Wei-Wu, Hsu, Chih-Hung, Yen, Yu-Hsin, Yang, James Chih-Hsin, Cheng, Ann-Lii, Sasaki, Shun-ichi, Chiu, LiYin (Lillian), Sugihara, Masahiro, Ishizuka, Tomoko, Oguma, Toshihiro, Tajima, Naoyuki, Lin, Chia-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985061/
https://www.ncbi.nlm.nih.gov/pubmed/30825104
http://dx.doi.org/10.1007/s10637-019-00745-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985061/
https://www.ncbi.nlm.nih.gov/pubmed/30825104
http://dx.doi.org/10.1007/s10637-019-00745-z

Ejemplares similares